653 results on '"Alam, S. Munir"'
Search Results
2. Influence of membrane on the antigen presentation of the HIV-1 envelope membrane proximal external region (MPER)
3. Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans
4. Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction
5. Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques
6. Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage
7. Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development
8. A Zika virus-specific IgM elicited in pregnancy exhibits ultrapotent neutralization
9. B cells expressing IgM B cell receptors of HIV-1 neutralizing antibodies discriminate antigen affinities by sensing binding association rates
10. mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice
11. Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity
12. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
13. Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies
14. Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants
15. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
16. The CH1 domain influences the expression and antigen sensing of the HIV-specific CH31 IgM-BCR and IgG-BCR.
17. A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy Individuals
18. Microsecond dynamics control the HIV-1 Envelope conformation
19. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
20. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research
21. Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection
22. Determinants of Tenascin-C and HIV-1 envelope binding and neutralization
23. Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual
24. Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions.
25. Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies
26. Class-specific sensing of HIV-1 antigens by the B cell antigen receptor depends on the CH1 domain
27. Cryptic-site-specific antibodies to the SARS-CoV-2 receptor binding domain can retain functional binding affinity to spike variants
28. Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier
29. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce β-chemokines
30. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines.
31. Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
32. Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth
33. A Therapeutic Antibody for Cancer, Derived from Single Human B Cells
34. Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody
35. Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site
36. Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques
37. Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations
38. Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies
39. Vaccine Induction of Heterologous HIV-1 Neutralizing Antibody B Cell Lineages in Humans
40. Vaccine induction of CD4-mimicking broadly neutralizing antibody precursors in macaques
41. A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies
42. Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies
43. Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies
44. Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved
45. Mutation-Guided Vaccine Design: A Strategy for Developing Boosting Immunogens for HIV Broadly Neutralizing Antibody Induction
46. An antibody from single human V H -rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion
47. A germline-targeting chimpanzee SIV envelope glycoprotein elicits a new class of V2-apex directed cross-neutralizing antibodies
48. HIV-1 antibodies and vaccine antigen selectively interact with lipid domains
49. Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies
50. HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.